MIRM - NASDAQ

Mirum Pharmaceuticals, Inc.

MIRM·NASDAQ

$91.83

-0.016%

HealthcareBiotechnology

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$4.61B

EPS-0.4700

P/E Ratio-195.39

Earnings Date07/30/2026

842.81M

Assets

26%

3Y+139.0%

5Y+250.0%

10Y+1522.0%

528.12M

Total Liabilities

19%

3Y+150.0%

5Y+668.0%

10Y+748.0%

314.69M

Total Equity

39%

3Y+122.0%

5Y+83.0%

10Y-3148.0%

Mirum Pharmaceuticals, Inc. Funding & Solvency Profile

MIRM · NASDAQ

Current Assets

Cash & Cash Equivalents296.68M

Net Receivables123.33M

Inventory24.89M

Other Current Assets18.14M

Total Current Assets550 M

Non-Current Assets

Property, Plant & Equipment0.00

Goodwill & Intangible Assets260.92M

Long-Term Investments8.11M

Other Non-Current Assets24.10M

Total Non-Current Assets32 M

Total Assets

842.81M

Financial Health Analysis

Current Ratio

2.67x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

1.68x

Elevated leverage. Debt exceeds equity, which amplifies both gains and risks. Monitor debt servicing ability.

Working Capital

344 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

65% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Mixed signals: Strong short-term liquidity provides comfort, but high overall leverage requires careful monitoring of debt servicing capabilities and refinancing risk.

Mirum Pharmaceuticals, Inc. Balance Sheet

MIRM • NASDAQ

Mirum Pharmaceuticals, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	296.7M	222.5M	286.3M	28M	31.3M	142.1M	12M	52M
Short-Term Investments	86.6M	57.8M	0.0	123.7M	125.2M	89.7M	104.7M	0.0
Cash & Short-Term Investments	383.3M	280.3M	286.3M	151.7M	156.5M	231.8M	116.7M	52M
Net Receivables	123.3M	78.3M	68M	24M	3.3M	0.0	0.0	0.0
Accounts Receivables	123.3M	78.3M	68M	24M	3.3M	0.0	0.0	0.0
Inventory	24.9M	22.4M	22.3M	5.6M	1.5M	0.0	0.0	0.0
Prepaids	0.0	0.0	0.0	0.0	5.3M	4.5M	2.7M	12K
Other Current Assets	18.1M	11.8M	10.9M	8.9M	0.0	0.0	0.0	12K
Total Current Assets	549.7M	392.8M	387.5M	190.2M	166.6M	236.4M	119.4M	52M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	0.0	9.8M	2M	2.3M	2.6M	3.2M	3.7M	0.0
Intangible Assets	260.9M	249.8M	252.9M	59M	18.7M	0.0	0.0	0.0
Goodwill & Intangible Assets	260.9M	249.8M	252.9M	59M	18.7M	0.0	0.0	0.0
Long-Term Investments	8.1M	12.5M	0.0	0.0	5M	0.0	23.3M	0.0
Other Non-Current Assets	24.1M	5.8M	4.2M	101.4M	101.8M	1.3M	324K	0.0
Total Non-Current Assets	293.1M	278M	259.1M	162.7M	128.1M	4.5M	27.3M	0.0
Total Assets	842.8M	670.8M	646.6M	352.9M	294.7M	240.9M	146.7M	52M
LIABILITIES
CURRENT LIABILITIES
Total Payables	9.6M	24M	14.1M	11.1M	9.8M	3.2M	3.4M	269K
Accounts Payable	9.6M	14.6M	7.4M	8.7M	9.2M	3.2M	3.4M	269K
Other Payables	0.0	9.4M	6.7M	2.5M	610K	0.0	0.0	0.0
Accrued Expenses	47.3M	68.6M	50.9M	36.9M	20.1M	8.6M	7.1M	2.2M
Short Term Debt	2.1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	0.0	1.7M	1.1M	931K	711K	636K	397K	0.0
Other Current Liabilities	146.8M	32.2M	20.9M	15.8M	12M	6.1M	2.2M	15K
Total Current Liabilities	205.8M	126.6M	87.1M	64.7M	42.6M	18.5M	13.1M	2.4M
NON-CURRENT LIABILITIES
Long Term Debt	309.8M	308.1M	306.4M	0.0	0.0	0.0	0.0	0.0
Deferred Revenue (Non-Current)	0.0	0.0	0.0	140.4M	129.9M	47.7M	0.0	0.0
Other Non-Current Liabilities	5M	2.5M	3.8M	4.5M	17K	29K	36K	59.8M
Total Non-Current Liabilities	322.3M	318.6M	310.9M	146.1M	131.8M	50.3M	3.3M	59.8M
Capital Lease Obligations	7.5M	9.7M	1.7M	2.2M	2.6M	3.3M	3.6M	0.0
Total Liabilities	528.1M	445.1M	398M	210.9M	174.4M	68.8M	16.4M	62.3M
SHAREHOLDERS' EQUITY
Treasury Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	66.8M
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	66.8M
Common Stock	5K	5K	5K	4K	3K	3K	2K	7M
Additional Paid-In Capital	981.9M	870.2M	803.3M	535.1M	377.4M	345.2M	200.1M	34K
Retained Earnings	-667.5M	-644.2M	-556.2M	-392.8M	-257.2M	-173.2M	-69.9M	-17.3M
Accumulated Other Comprehensive Income/Loss	351K	-373K	1.6M	-217K	-35K	83K	129K	-66.8M
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	66.8M
Total Stockholders' Equity	314.7M	225.6M	248.7M	142M	120.2M	172.1M	130.3M	-10.3M
Total Equity	314.7M	225.6M	248.7M	142M	120.2M	172.1M	130.3M	-10.3M
SUMMARY
Total Liabilities & Equity	842.8M	670.8M	646.6M	352.9M	294.7M	240.9M	146.7M	52M
Total Investments	94.7M	70.3M	0.0	123.7M	130.2M	89.7M	128M	0.0
Total Debt	319.5M	317.8M	308.1M	2.2M	2.6M	3.3M	3.6M	0.0
Net Debt	22.8M	95.3M	21.8M	-25.8M	-28.7M	-138.8M	-8.3M	-52M
Shares Outstanding	49,355,997	49,355,997	49,355,997	49,355,997	49,355,997	49,355,997	49,355,997	49,355,997

SEC Filings

MIRM - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 18, 2026	May 12, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 06, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 06, 2026	May 06, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 04, 2026	May 04, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 27, 2026	April 27, 2026	2026	View Filing
DEF 14A DEF 14A 2025 N/A	April 23, 2026	December 31, 2025	2025	View Filing
8-K/A 8-K/A 2026 (Amended) N/A	April 08, 2026	January 23, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 25, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 25, 2026	February 25, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 26, 2026	January 23, 2026	2026	View Filing

Showing 1 to 10 of 123 filings

Related Guides

Blog Categories

Continue your MIRM research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.